Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 45 years of age or older, of any gender
- People who have been diagnosed with Parkinson's disease based on a specific set of established diagnostic guidelines (known as the UK Parkinson's Disease Society Brain Bank Criteria)
- People who have a specific gene change called an LRRK2 mutation, confirmed through a referral from the UM Movement Disorders clinic, a review of medical records, or previous participation in a study called PDGENEration
Who may not be able to join:
- People who show signs of an atypical (unusual) form of parkinsonism rather than standard Parkinson's disease
- People who have medical devices or conditions that make MRI scans unsafe, such as a pacemaker, aneurysm clips, metal in the eye, a cochlear implant, or severe claustrophobia
- People whose MRI scan shows evidence of a large stroke or an abnormal growth in the brain
- People who regularly take certain types of medications known as typical anticholinergic drugs or cholinesterase inhibitors (confirm with trial site)
- People who have previously had deep brain stimulation surgery
- People who are currently pregnant or breastfeeding
- People who are experiencing thoughts of suicide, as identified by responses to a standard questionnaire (the Beck Depression Inventory)
- People whose level of cognitive difficulty means they are unable to give informed consent, as assessed using a specific decision-making capacity tool
- People who have any other condition that would make safe or meaningful participation in the study unsuitable (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Prabesh Kanel, PhD, University of Michigan
Phone: 734-998-6894
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Cholinergic Differences Between leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease (PD) and Idiopathic/non-LRRK2 PD (iPD); Dopaminergic Differences Between LRRK2-PD and iPD; Association of Cholinergic Data With Cognition in LRRK2-PD; Association of Cholinergic Data With Postural Instability and Gait Difficulties (PIGD) in LRRK2-PD; Association of Dopaminergic Data With Cognition in LRRK2-PD; Association of Dopaminergic Data With PIGD in LRRK2-PD
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.